Nieuws en video's - Q BIOMED INC. QBIO

Q BioMed Inc. Provides Update to Shareholders PR Newswire NEW YORK, July 29, 2022 Company Reports Revenue Improvement and Positive Data on Pipeline Assets NEW YORK , July 29, 2022 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO) a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthcare sector, has seen an uptick in Strontium89 sales revenue in its recently reported quarter. Revenue in Q2 was up 100% vs Q1 representing the...

Strontium89 Now Reimbursed in Hospital and Outpatient Settings for Metastatic Bone Pain Treatment Strontium89 Now Reimbursed in All Treatment Settings PR Newswire NEW YORK, Jan. 7, 2021 NEW YORK , Jan. 7, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that the Centers for Medicare and Medicaid Services (CMS) updated the Outpatient Prospective Payment System (OPPS) reimbursement rate for its FDA approved non-opioid metastatic bone pain drug...

Q BioMed Updates Shareholders at Year End Company Expects Several Milestones as Momentum Builds for 2021 PR Newswire NEW YORK, Dec. 29, 2020 NEW YORK , Dec. 29, 2020 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO ), a commercial stage biotech company, today issued a letter to shareholders. Dear Fellow Shareholders, As 2020 draws to a close, we join the rest of the world in looking forward to a new year with new beginnings and hope for a quick return to whatever the new normal will be. Leaving behind...

Q BioMed Announces Strontium89 will be available as of September 2020 through Named Patient Program for Bone Metastases Pain Palliation in EU and Rest of World - Named Patient Programs will allow Providers to treat patients with bone metastases pain palliation radiopharmaceutical treatment as of September, 2020 - Named Patient Programs will remain in place until the treatment has been commercialised in EU and ROW, which is expected to be completed in 2021 PR Newswire NEW YORK, Aug. 11, 2020 NEW...

Q Biomed to Scale up Production of Uttroside-B, a Novel Chemotherapeutic for Liver Cancer, in Preparation for IND Filing PR Newswire NEW YORK, July 22, 2020 Q BioMed continues its collaboration with Chemveda Life Sciences to prepare for pre-clinical evaluation, Orphan Drug filing and Investigational New Drug (IND) filing of Uttroside-B Novel Therapeutic Shows Remarkable Efficacy in HepG2 Cell Lines NEW YORK , July 22, 2020 /PRNewswire/ -- Q BioMed, Inc. (OTCQB: QBIO) and Chemveda Life Sciences...

Q BioMed Announces Global Distribution Partnership With Caligor Coghlan Pharma Services for its Non-Opioid Cancer Palliation Drug Caligor Coghlan Pharma Services to Distribute Strontium89 (Strontium Chloride Injection Sr-89 USP) Outside the United States Agreement opens international markets ahead of schedule under Named Patient Program PR Newswire NEW YORK, July 8, 2020 NEW YORK , July 8, 2020 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today it...

Q BioMed Enters into a Financial Restructuring of Approximately $7,800,000 Consisting of $4,000,000 New Cash and a Minimum of $3,800,000 of Debt Conversion Sets Roadmad to Uplisting and Provides Cash Runway to 2021 and Beyond PR Newswire NEW YORK, April 7, 2020 NEW YORK , April 7, 2020 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO ), a commercial stage biotech company, announced today the entering of a significant financial transaction with its lead investor, Yorkville Advisors Global ("YA"). Under...

Q BioMed Adds to Leadership Team With Global Head of Regulatory Affairs Initial focus on global rollout of Strontium89 PR Newswire NEW YORK, March 31, 2020 NEW YORK , March 31, 2020 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO ), a commercial stage biotech company, announced today the appointment of Geoff Fatzinger as the Global Head of Regulatory Affairs. Geoff will be responsible for providing strategic regulatory oversight to Q BioMed for product development and commercialization. Specifically,...

Q BioMed Expands Leadership Team With Chief Commercial Officer Commercializing Strontium89 and guiding strategic development of earlier stage assets PR Newswire NEW YORK, March 30, 2020 NEW YORK , March 30, 2020 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO ), a commercial stage biotech company, announced today the appointment of Kristin Keller to the newly created position of Chief Commercial Officer. Kristin will be focused on driving the global commercialization of Q BioMed's lead product, the...

Q BioMed Treats its First Patient in Commercial Setting Following Product Launch - Full commercial launch expected in the coming weeks of March - An estimated 10 million people are living worldwide with pain from bone metastases PR Newswire NEW YORK, March 12, 2020 NEW YORK , March 12, 2020 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO ), a commercial stage biotech company, announced today the first patient has been dosed in a commercial setting with its U.S. FDA approved non-opioid drug...

Q BioMed Provides a Shareholder Update Ahead of the Commercial Launch of its First Drug PR Newswire NEW YORK, Jan. 7, 2020 NEW YORK , Jan. 7, 2020 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO ), a commercial stage biotech company, is pleased to provide the following shareholder letter. Q BioMed's goal is to license and acquire undervalued biomedical assets in the healthcare sector. Since the Company's inception, 4.5 years ago, it has been busy building significant value ranging from blockbuster...

...

Q BioMed Technology Partner Mannin Research Inc. Presents Data Showing Potential Treatment to Protect the Kidney in Acute Kidney Injury Using Mannin Tie2 Activator Data presented during "Acute Kidney Injury" symposium at the American Society for Nephrology 2019 Annual Meeting Expands Pipeline of Platform Technology PR Newswire NEW YORK, Nov. 26, 2019 NEW YORK , Nov. 26, 2019 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, is announcing today that its technology...

...

Q BioMed Announces FDA Approval Company Gets Green Light for Manufacturing FDA Approved Non-Opioid Cancer Palliation Drug PR Newswire NEW YORK, Nov. 20, 2019 NEW YORK , Nov. 20, 2019 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), announces FDA approval of its contract manufacturer IsoTherapeutics Group LLC (ITG). ITG is now cleared to manufacture the Company's FDA approved non-opioid cancer bone pain drug Strontium-89 Chloride USP. The long-awaited approval of the facility means that this...

...

Q BioMed Announces $7.5M Grant Benefiting its Preclinical Product Development Pipeline Grant Awarded to Q BioMed Partner Mannin GmbH in the Amount of EUR 6.95M PR Newswire NEW YORK, Nov. 5, 2019 NEW YORK , Nov. 5, 2019 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO ), a commercial stage biotech company, announced today that its technology partner, Mannin , has received a $7.5M grant from the German state of Saxony. Mannin is a research-stage biotechnology company focused on the discovery,...

...

Q BioMed Announces Commercial Partnership With Jubilant Radiopharma for the Distribution of its Non-Opioid Cancer Palliation Drug in the United States Jubilant Radiopharma to Distribute Strontium-89 Chloride Injection USP Throughout the United States PR Newswire NEW YORK, Oct. 3, 2019 NEW YORK , Oct. 3, 2019 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO ), a commercial stage biotech company, announced today it has entered into an exclusive distribution agreement for its non-opioid metastatic cancer...

Q BioMed Announces Legal Settlement and Acquisition of FDA Approved Non-Opioid Metastatic Cancer Pain Drug Company Settles Legal Action Resulting in Outright Ownership of the Drug Preparing for Commercial Launch PR Newswire NEW YORK, Oct. 2, 2019 NEW YORK , Oct. 2, 2019 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), is pleased to report that it has entered into a settlement agreement with BioNucleonics Inc. to complete the outright acquisition of the non-opioid cancer bone pain drug Strontium-89...